• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤微环境对溶瘤病毒治疗的影响。

Impact of tumor microenvironment on oncolytic viral therapy.

机构信息

Dardinger Laboratory for Neuro-oncology and Neurosciences, Department of Neurological Surgery, James Comprehensive Cancer Center, Columbus, OH 43210, United States.

出版信息

Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):127-34. doi: 10.1016/j.cytogfr.2010.02.014.

DOI:10.1016/j.cytogfr.2010.02.014
PMID:20399700
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2881175/
Abstract

Interactions between tumor cells and their microenvironment have been shown to play a very significant role in the initiation, progression, and invasiveness of cancer. These tumor-stromal interactions are capable of altering the delivery and effectiveness of therapeutics into the tumor and are also known to influence future resistance and re-growth after treatment. Here we review recent advances in the understanding of the tumor microenvironment and its response to oncolytic viral therapy. The multifaceted environmental response to viral therapy can influence viral infection, replication, and propagation within the tumor. Recent studies have unveiled the complicated temporal changes in the tumor vasculature post-oncolytic virus (OV) treatment, and their impact on tumor biology. Similarly, the secreted extracellular matrix in solid tumors can affect both infection and spread of the therapeutic virus. Together, these complex changes in the tumor microenvironment also modulate the activation of the innate antiviral host immune response, leading to quick and efficient viral clearance. In order to combat these detrimental responses, viruses have been combined with pharmacological adjuvants and "armed" with therapeutic genes in order to suppress the pernicious environmental conditions following therapy. In this review we will discuss the impact of the tumor environment on viral therapy and examine some of the recent literature investigating methods of modulating this environment to enhance oncolysis.

摘要

肿瘤细胞与其微环境之间的相互作用已被证明在癌症的发生、进展和侵袭性方面起着非常重要的作用。这些肿瘤-基质相互作用能够改变治疗药物在肿瘤中的传递和效果,并且已知会影响治疗后的未来耐药性和再生长。在这里,我们回顾了对肿瘤微环境及其对溶瘤病毒治疗反应的理解的最新进展。对病毒治疗的多方面环境反应会影响病毒在肿瘤内的感染、复制和传播。最近的研究揭示了溶瘤病毒(OV)治疗后肿瘤血管的复杂时变及其对肿瘤生物学的影响。同样,实体瘤中分泌的细胞外基质也会影响治疗病毒的感染和传播。总之,肿瘤微环境的这些复杂变化也调节了先天抗病毒宿主免疫反应的激活,导致病毒迅速有效地清除。为了对抗这些有害反应,已经将病毒与药理佐剂结合,并“武装”了治疗基因,以抑制治疗后有害的环境条件。在这篇综述中,我们将讨论肿瘤环境对病毒治疗的影响,并研究一些最近的文献,探讨调节这种环境以增强溶瘤的方法。

相似文献

1
Impact of tumor microenvironment on oncolytic viral therapy.肿瘤微环境对溶瘤病毒治疗的影响。
Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):127-34. doi: 10.1016/j.cytogfr.2010.02.014.
2
Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.肿瘤的双重困境:利用肿瘤微环境增强溶瘤病毒的抗癌效果。
Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):135-41. doi: 10.1016/j.cytogfr.2010.02.007. Epub 2010 Mar 24.
3
Understanding the interplay between oHSV and the host immune system: Implications for therapeutic oncolytic virus development.了解单纯疱疹病毒溶瘤株(oHSV)与宿主免疫系统之间的相互作用:对治疗性溶瘤病毒开发的启示。
Mol Ther. 2025 Apr 2;33(4):1327-1343. doi: 10.1016/j.ymthe.2024.12.054. Epub 2024 Dec 30.
4
Integrating oncolytic viruses in combination cancer immunotherapy.将溶瘤病毒整合到联合癌症免疫疗法中。
Nat Rev Immunol. 2018 Aug;18(8):498-513. doi: 10.1038/s41577-018-0014-6.
5
Employing the Oncolytic Vesicular Stomatitis Virus in Cancer Virotherapy: Resistance and Clinical Considerations.溶瘤性水疱性口炎病毒在癌症病毒治疗中的应用:耐药性及临床考量
Viruses. 2024 Dec 25;17(1):16. doi: 10.3390/v17010016.
6
Oncolytic viruses for induction of anti-tumor immunity.溶瘤病毒诱导抗肿瘤免疫。
Curr Pharm Biotechnol. 2012 Jul;13(9):1750-60. doi: 10.2174/138920112800958913.
7
The evolving landscape of oncolytic virus immunotherapy: combinatorial strategies and novel engineering approaches.溶瘤病毒免疫疗法的发展态势:联合策略与新型工程方法
Med Oncol. 2025 May 2;42(6):190. doi: 10.1007/s12032-025-02746-w.
8
Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.使用组蛋白去乙酰化酶抑制剂和免疫检查点阻断克服溶瘤病毒疗法中的障碍。
Viruses. 2016 Jan 6;8(1):9. doi: 10.3390/v8010009.
9
Oncolytic Virotherapy and the Tumor Microenvironment.溶瘤病毒治疗与肿瘤微环境。
Adv Exp Med Biol. 2017;1036:157-172. doi: 10.1007/978-3-319-67577-0_11.
10
Immunomodulation in Oncolytic Measles Virotherapy.溶瘤麻疹病毒疗法中的免疫调节
Methods Mol Biol. 2020;2058:111-126. doi: 10.1007/978-1-4939-9794-7_7.

引用本文的文献

1
Systemic Delivery Strategies for Oncolytic Viruses: Advancing Targeted and Efficient Tumor Therapy.溶瘤病毒的全身递送策略:推进靶向高效肿瘤治疗
Int J Mol Sci. 2025 Jul 18;26(14):6900. doi: 10.3390/ijms26146900.
2
Oncolytic Viruses in Ovarian Cancer: Where Do We Stand? A Narrative Review.卵巢癌中的溶瘤病毒:我们目前的进展如何?一篇叙述性综述。
Pathogens. 2025 Feb 3;14(2):140. doi: 10.3390/pathogens14020140.
3
An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas.恶性脑胶质瘤溶瘤病毒治疗的临床现状、挑战与未来方向的更新。
Curr Treat Options Oncol. 2024 Jul;25(7):952-991. doi: 10.1007/s11864-024-01211-6. Epub 2024 Jun 19.
4
TheraVision: Engineering platform technology for the development of oncolytic viruses based on herpes simplex virus type 1.TheraVision:基于1型单纯疱疹病毒的溶瘤病毒开发的工程平台技术。
Mol Ther Oncol. 2024 Feb 28;32(1):200784. doi: 10.1016/j.omton.2024.200784. eCollection 2024 Mar 21.
5
Agent-Based and Continuum Models for Spatial Dynamics of Infection by Oncolytic Viruses.基于主体和连续统模型的溶瘤病毒感染的空间动力学。
Bull Math Biol. 2023 Aug 31;85(10):92. doi: 10.1007/s11538-023-01192-x.
6
Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma.溶瘤病毒疗法治疗胶质母细胞瘤的现状与挑战
Pharmaceuticals (Basel). 2023 May 26;16(6):793. doi: 10.3390/ph16060793.
7
Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy.过继性细胞疗法与溶瘤病毒疗法联合应用的机遇与挑战
Mol Ther Oncolytics. 2023 May 4;29:118-124. doi: 10.1016/j.omto.2023.04.008. eCollection 2023 Jun 15.
8
Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment.间充质干细胞释放的溶瘤病毒:一种创新的癌症治疗策略。
Cell Commun Signal. 2023 Feb 24;21(1):43. doi: 10.1186/s12964-022-01012-0.
9
Modifying oncolytic virotherapy to overcome the barrier of the hypoxic tumor microenvironment. Where do we stand?改良溶瘤病毒疗法以克服缺氧肿瘤微环境的障碍。我们目前的进展如何?
Cancer Cell Int. 2022 Nov 24;22(1):370. doi: 10.1186/s12935-022-02774-w.
10
Tumour microenvironment: Modulating effects, challenges, and future perspectives of oncolytic virotherapy in Astrocytoma treatment.肿瘤微环境:溶瘤病毒疗法在星形细胞瘤治疗中的调节作用、挑战及未来展望
Ann Med Surg (Lond). 2022 Aug 28;82:104508. doi: 10.1016/j.amsu.2022.104508. eCollection 2022 Oct.

本文引用的文献

1
Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.对经基因工程改造以表达碘化钠同向转运体的麻疹病毒埃德蒙斯顿株进行全身给药的I期试验,用于复发性或难治性多发性骨髓瘤患者。
Leukemia. 2017 Dec;31(12):2791-2798. doi: 10.1038/leu.2017.120. Epub 2017 Apr 25.
2
Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy.几丁质酶对克服细胞外基质障碍的影响用于溶瘤病毒治疗。
Gene Ther. 2010 Feb;17(2):190-201. doi: 10.1038/gt.2009.142. Epub 2009 Nov 12.
3
Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.抗血管生成武装的溶瘤痘病毒增强了肾细胞癌模型的抗肿瘤疗效。
J Virol. 2010 Jan;84(2):856-66. doi: 10.1128/JVI.00692-09. Epub 2009 Nov 11.
4
"Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment.“买一送一”:武装病毒用于治疗癌细胞及其微环境。
Curr Gene Ther. 2009 Oct;9(5):341-55. doi: 10.2174/156652309789753329.
5
Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1.表达血管抑素(Vstat120)的溶瘤单纯疱疹病毒 1 增强抗肿瘤疗效。
Mol Ther. 2010 Feb;18(2):285-94. doi: 10.1038/mt.2009.232. Epub 2009 Oct 20.
6
Cellular effects of oncolytic viral therapy on the glioblastoma microenvironment.溶瘤病毒治疗对脑胶质瘤微环境的细胞效应。
Gene Ther. 2010 Feb;17(2):202-16. doi: 10.1038/gt.2009.130. Epub 2009 Oct 15.
7
Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy.溶瘤痘苗病毒编码的抗VEGF单链抗体GLAF-1显著增强抗肿瘤治疗效果。
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12915-20. doi: 10.1073/pnas.0900660106. Epub 2009 Jul 15.
8
Hypoxia enhances the replication of oncolytic herpes simplex virus in p53- breast cancer cells.缺氧增强了溶瘤性单纯疱疹病毒在p53基因缺陷型乳腺癌细胞中的复制。
Cell Cycle. 2009 Jul 15;8(14):2194-7. doi: 10.4161/cc.8.14.8934. Epub 2009 Jul 6.
9
Pharmacologic and chemical adjuvants in tumor virotherapy.肿瘤病毒疗法中的药理和化学佐剂。
Chem Rev. 2009 Jul;109(7):3125-40. doi: 10.1021/cr900048k.
10
Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment.Ad5/3-9HIF-Delta24-VEGFR-1-Ig,一种感染性增强的、双靶点的、抗血管生成的溶瘤腺病毒,用于治疗肾癌。
Gene Ther. 2009 Aug;16(8):1009-20. doi: 10.1038/gt.2009.56. Epub 2009 May 14.